Regen BioPharma Inc (RGBP)

[Skiluc]

Ongoing Agreement With Eli Lilly Leads to Discovery of Several New Small Molecule Drugs
$RGBP - Regen BioPharma, Inc. (OTCQBRGBP & RGBPP)

Summary:

Eli Lilly Agreement
Milestones Surpassed
Developing New Small Molecule Drugs
Cancer
Lupus

The compounds, thousands upon thousands Regen has tested are Provided by Eli Lilly and Co. ( LLY ) via a Collaborative Agreement that States - Eli Lilly has the Right to License or Purchase Any/All Developed Compounds and New Drugs.

Recently Regen announced Two New Milestones that have led to the Discovery of Several New Small Molecule Drugs that have potential Cancer-Killing effects and Proven success treating Lupus.

Cancer Treatment

They Have Identified a Series of Small Molecule Drugs that Inhibit NR2F6 & also Activate Human Immune Cells ex-vivo.

Evidence has been provided by studies suggesting the new drugs Repress the Body's Immune Response Against Tumors and activate T-Cells that have potential Cancer-Killing Effects.

While Preliminary these Results are Extremely Encouraging. The Agonists are Behaving as Regen Hoped & Expected They Would. These are very exciting times at Regen as the make major leaps now in progress with their program for Cancer treatment.

Autoimmune Therapies

Regen also reported success with their Small Molecule Program and Drugs that inhibit NR2F6 and the treatment of Autoimmune Diseases recently.

Their screening process demonstrated that they have identified the NR2F6 nuclear receptor as a potential, very important immune cell inhibitor (an immune checkpoint). This is critical in developing therapies for treating autoimmune diseases.

These novel chemical compounds have shown success and the potential for treating autoimmune diseases such as Lupus. Regen's Lead Drug Candidate, RG-NAE005 was tested for the maximum dosage and showed no signs of toxicity, or cytotoxicity. This exhibited as a single dose of 2,000 mg/kg and repeated doses of 400 mg/kg.

This is very exciting, as it indicates that the drug will likely be safe in animals as they move forward and begin the efficacy phase of trials.

We think RGBP is a Long Play with Short Term Gain Potential. The Support and Volume has increased and it has shown the potential to bounce up. Recently over 100%. It has retraced giving back all that it gained. Profit taking and more than likely the maturation of Debt Equity financing. Could be an opportunity at this level for new investors, or cost averaging for existent shareholders.

Keep in mind Eli Lilly reserves the right to license and or purchase any compounds developed, and/or new drugs. Regen could be an attractive merge-buyout target at some point.

https://www.hvst.com/posts/ongoing-agreement-with-eli-lilly-leads-to-discovery-of-several-new-small-molecule-drugs-wm4T1ZDp